



Commercial/Healthcare Exchange PA Criteria

Effective: October 18th, 2019

Prior Authorization: Turalio

Products Affected: Turalio (pexidartinib) oral capsules

Medication Description: Turalio, a tyrosine kinase inhibitor, is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Turalio targets the colony stimulating factor 1 (CSF1) receptor; it also inhibits KIT proto-oncogene receptor tyrosine kinase, as well as FMS-like tyrosine kinase 3 with an internal tandem duplication mutation. Due to the risk of hepatotoxicity, Turalio is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.

Covered Uses: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis

Age Restrictions: 18 years of age or older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist.

Coverage Duration: 3 years

Other Criteria:

1. The patient has a diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity (i.e. disability or degeneration of affected joint) or functional limitations (i.e. limitation of joint movement); AND
2. The tumor is not amenable to improvement with surgery.

References:

1. Turalio™ [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; August 2019.
2. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2019.

Last Res.10.18.2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|--------------|-----------------------|--------------------------|--------------------------|-------------|
| 1 | New Policy | New Policy | All | 10/18/19 |